Akili
$0.48
8
+$0.01+2.3% Wednesday 21:30
Statistics
Day High
0.5
Day Low
0.46
52W High
2.2
52W Low
0.33
Volume
6,354
Avg. Volume
50,235
Mkt Cap
37.65M
P/E Ratio
0
Dividend Yield
-
Dividend
-
Upcoming
Earnings
5MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.37
0.01
0.38
0.76
Expected EPS
-0.2033
Actual EPS
0
People Also Follow
This list is based on the watchlists of people on Stock Events who follow AKLI. It's not an investment recommendation.
Analyst Ratings
4$Average Price Target
The highest estimate is $4.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive dysfunction. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine design to target neutral system, such as focus, interference processing, and multitasking; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company is headquartered in Boston, Massachusetts.
Show more...
CEO
Dr. Walter Edward Martucci Ph.D.
Employees
109
Country
United States
ISIN
US00974B1070